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Yaws is targeted for eradication by 2020. The mainstay of 
the eradication strategy is mass treatment followed by case 
finding. Modeling has been used to inform programmatic re-
quirements for other neglected tropical diseases and could 
provide insights into yaws eradication. We developed a 
model of yaws transmission varying the coverage and num-
ber of rounds of treatment. The estimated number of cas-
es arising from an index case (basic reproduction number 
[R0]) ranged from 1.08 to 3.32. To have 80% probability of 
achieving eradication, 8 rounds of treatment with 80% cov-
erage were required at low estimates of R0 (1.45). This re-
quirement increased to 95% at high estimates of R0 (2.47). 
Extending the treatment interval to 12 months increased 
requirements at all estimates of R0. At high estimates of R0 
with 12 monthly rounds of treatment, no combination of vari-
ables achieved eradication. Models should be used to guide 
the scale-up of yaws eradication.
Yaws is a bacterial infection caused by Treponema pal-lidum subsp. pertenue (1). The disease predominantly 
affects children living in poor, remote communities and re-
sults in lesions of the skin, bone, and cartilage. Previously, 
yaws was widespread throughout the tropics (2), but in 
the 20th century a series of control efforts based on mass 
treatment and case finding led by the World Health Organi-
zation (WHO) is estimated to have reduced the burden of 
cases worldwide by up to 95% (3). Despite these efforts, 
the disease has resurged in several countries in West and 
Central Africa, the Pacific, and Southeast Asia.
In 2012, a single dose of azithromycin was shown to 
be effective treatment for yaws (4). The availability of a 
well-tolerated oral agent has prompted WHO to develop 
a new eradication strategy, known as the Morges strategy, 
based on community mass azithromycin treatment (5). The 
strategy is supported by World Health Assembly resolu-
tion 66.12, which calls for eradication of yaws by 2020 (6). 
The strategy combines an initial round of total community 
treatment (TCT) followed by subsequent active case find-
ing and total targeted treatment (TTT) of newly identified 
patients and their contacts. Pilot studies have shown that 
community mass treatment with azithromycin is a highly 
effective strategy for reducing the community prevalence 
of yaws (7,8).
Data are limited to inform the optimum coverage and 
number of TCT or TTT rounds that are required to achieve 
elimination (i.e., interruption of transmission) of yaws at a 
local level to facilitate country-level elimination and ulti-
mately global eradication. In India, a national yaws elimi-
nation campaign conducted during 1996–2004 resulted in 
substantial reduction in the prevalence of yaws, sustained 
interruption of transmission, and nationwide elimination 
(9). This program consisted of case-finding surveys and 
treatment with parenteral penicillin conducted every 6 
months. Although this approach did not include the initial 
mass treatment round now recommended as part of the 
Morges strategy, its success indicates that serial rounds of 
high-coverage treatment might achieve local elimination.
A recent review of important research questions fac-
ing the global yaws eradication program has highlighted 
the need for more accurate data to inform the optimum 
number and coverage of rounds of TCT and TTT that will 
be required to achieve yaws eradication (10). Mathematical 
modeling has been used to inform control efforts for sev-
eral other neglected tropical diseases (11–13) that are also 
managed by using community mass treatment strategies, 
and such approaches could be of value for yaws eradication 
efforts. In particular, this approach might allow a compari-
son of the differential effects of alternative mass treatment 
strategies, which would be difficult to assess by empirical 
randomized controlled trials because of the size and cost of 
implementing large-scale cluster randomized studies.
Previous mathematical models for yaws (14) have as-
sessed the cost-effectiveness of yaws eradication but have 
not directly addressed the feasibility of achieving this 
goal or the number of rounds of treatment that would be 
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required. In this study, we aimed to determine whether the 
eradication of yaws is feasible based on the Morges strat-
egy and, if it is, the number and coverage of mass treatment 
rounds needed to achieve the goal.
Methods
We developed a stochastic Markov model of community-
level transmission of yaws (Figure 1). This model treats 
each stage of the disease as a discrete compartment, with 
persons moving through each compartment as the disease 
progresses or is treated. Upon infection, susceptible per-
sons acquire primary disease at a rate that is proportional to 
the transmission rate and the total number of infectious per-
sons. Persons with primary disease can further transition to 
secondary disease, at which stage they remain infectious, 
and both those with primary and secondary disease can tran-
sition to latent disease, which is not infectious. Last, those 
with latent disease can relapse back to secondary infectious 
disease. The model includes a rate of routine treatment for 
persons with primary or secondary disease, after which 
they become susceptible to infection again. The model also 
includes a lower rate of routine treatment for latent disease, 
after which the patients also become susceptible to infec-
tion again. Unlike previous mathematical models of yaws 
(14), tertiary yaws was not included in the model because 
such cases are believed not to contribute to transmission 
(15). Because persons might be reinfected many times, we 
did not consider them to obtain protective immunity after 
infection or treatment (online Technical Appendix, http://
wwwnc.cdc.gov/EID/article/23/1/16-0487-Techapp1.pdf).
Although some evidence suggests the existence of a 
nonhuman primate reservoir for yaws in Africa (16), we 
did not include such infections in our model because there 
is currently no definitive evidence that the organism re-
sponsible for these infections is the same one that causes 
human yaws or that zoonotic transmission occurs in the real 
world. We therefore considered the epidemiologic impor-
tance of this possible reservoir as minimal when construct-
ing our model.
Population Size
Estimates of the starting population for each compartment 
were derived from published population-based yaws preva-
lence studies (7,17). We modeled a discrete closed popula-
tion without addition or reduction through births or deaths.
Disease Characteristic Variable Estimates
We estimated values for the rates of disease progression 
between different stages of yaws, including development 
of and relapse from latent yaws, by using expert opin-
ion, published data, and estimates used in other models 
(Table 1) (1,14,17). We defined 3 transmission scenarios 
(low, medium, and high) by using published age-specific 
treponemal seroprevalence data (17), expert opinion, and 
values used in other yaws models (14). Based on these 
data, we calculated initial estimates of the number of new 
infections arising from a single index case in a fully sus-
ceptible population (the basic reproduction number [R0]). 
Based on the seroprevalence data, we generated R0 esti-
mates of 1.25 (low), 1.83 (medium), and 2.4 (high). These 
estimates were converted to estimates of the probability 
of transmission after contact between an infectious person 
and a susceptible persons (β). The mean R0 taking account 
of the full structure of our model, including duration of 
infection and the size of each starting population, is 1.96, 
resulting in a mean R0 of 1.45 (95% CI 1.01–2.14) for the 
low transmission settings, 1.95 (95% CI 1.38–2.91) for 
medium, and 2.47 (95% CI 1.7–3.68) for high transmis-
sion. We included a variable to represent the likelihood 
of a person receiving treatment for yaws in the absence of 
public health interventions based on published data (17).
Mass Drug Administration Variables Estimates
We performed simulation experiments to estimate the im-
pact of a yaws eradication intervention on disease transmis-
sion. In line with the Morges strategy (5), we considered 2 
program components. In the first component, TCT, all per-
sons were considered to have an equal chance of receiving 
treatment regardless of their infection status. In the second 
component, TTT, we considered that the coverage achieved 
among persons with active infection and those with latent 
infection might differ. Intervention coverage was modeled 
independently for TCT, with TTT pertaining to persons 
with active infection and persons with latent infection over 
a range of plausible estimates (65%–95% population cov-
erage). Mass treatment compliance was simulated as a ran-
dom, nonsystematic process (i.e., each person had the same 
Figure 1. Markov model of yaws transmission. Susceptible 
persons become infected at a rate dependent on the probability 
of transmission and the number of persons with infectious primary 
and secondary yaws. Without treatment, illness progresses from 
primary disease to either latent yaws or secondary yaws. Persons 
with latent yaws might relapse to generate secondary cases of 
infectious yaws in others.
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chance of receiving treatment, with the likelihood of any 1 
person receiving treatment being independent).
We varied the number of treatment rounds of TCT (1–3 
rounds) and TTT (0–5 rounds). Where >1 rounds of TTT 
were implemented, these rounds followed the final round 
of TCT. In line with the Morges strategy and real-world 
pilot implementations (5,7), rounds of mass treatment were 
spaced at 6-month intervals. We also conducted an analysis 
with rounds of treatment spaced at 12-month intervals to 
assess whether annual treatment might also be effective.
We derived estimates of the efficacy of single-dose 
treatment with azithromycin from randomized controlled 
trials of azithromycin for the treatment of yaws (Table 1) 
(4). After successful treatment, yaws lesions become non-
infectious within 24 hours (1); therefore, we considered 
treatment to be immediately efficacious at the time of mass 
drug administration, with persons reverting to a susceptible 
state after treatment.
Implementing the Model
The model was implemented in R software (19). We per-
formed repeated simulations across a range of assumptions 
about the rate of transmission (equivalent to low, medium, 
and high estimates of R0) and assumptions about mass 
treatment, varying the coverage and number of mass treat-
ment rounds undertaken (Table 1).
For each combination of disease and intervention pa-
rameters, we performed 1,000 simulation experiments. 
Within each combination of transmission and treatment 
assumptions, we varied other disease-specific variables 
(e.g., rate of progression and relapse and treatment in the 
absence of intervention) across the range of parameter 
estimates. The model was run for an initial period of 50 
months to achieve a steady state with yaws eradication in-
terventions modeled to commence after this initial period. 
The model then ran for a further 100 months (online Tech-
nical Appendix).
Assessing Outcomes
For each run of the model, we recorded whether eradication 
was achieved. Eradication was defined as no cases of infec-
tious or latent yaws at the end of the model run. The eradi-
cation probability was defined as the percentage of runs 
within each permutation of model characteristics where 
eradication was achieved. All analyses were performed by 
using R version 3.2.2.
Results
The model generated a total of 6,174 simulations of vari-
able mass drug administration strategies. Because each 
strategy was implemented across a range (n = 3) of as-
sumptions about the force of infection, a total of 18,522 
simulations were created. The probability of achieving lo-
cal interruption of transmission varied substantially across 
estimates of the force of infection and mass drug adminis-
tration characteristics.
 
Table 1. Parameters used in modeling treatment coverage required to achieve yaws eradication 
Parameter 
Parameter 
estimate Source of estimate Comments 
Epidemiologic parameters 
 R0* 1.08–3.32 Derived from 
published survey 
data (17) 
The average number of new cases 
occurring from a single index case in a 
fully susceptible population 
 Monthly probability of progression from  
 primary to secondary disease without 
 treatment 
2.78%–5.56% Derived from expert 
opinion and 
previously published 
models (1,14) 
 
All untreated persons with primary disease 
either develop secondary or latent stage 
disease, and this occurs over a period of 
2–6 mo. Untreated persons with latent 
cases might relapse for a period of >5 y 
and become actively infectious again. 
 Monthly probability of progression from  
 infectious to latent disease without treatment 
13.9%–27.8% 
 Monthly probability of relapse from latent  
 disease to infectious stage without treatment 
1%–3% 
Population parameters  
 Susceptible at baseline 64% Derived from 
published survey 
data (17) 
 
Data derived from multiple pre–mass drug 
administration surveys conducted in 
communities where yaws is endemic 
 Primary yaws at baseline 1.5% 
 Secondary yaws at baseline 1.5% 
 Latent yaws at baseline 33% 
Mass treatment parameters 
 Total community treatment coverage† 65%–95% Expert opinion and 
published data on 
coverage achieved 
in other mass 
treatment campaigns 
(18) 
 
Coverage estimates were chosen to reflect 
the range achieved in real-world mass 
drug administration programs for other 
neglected tropical diseases 
 Total targeted treatment coverage of persons  
 with active cases‡ 
65%–95% 
 Total targeted treatment coverage of persons  
 with latent cases‡ 
65%–95% 
 No. rounds of total community treatment† 1–3  
 No. rounds of total targeted treatment‡ 0–5  
*R0 (basic reproduction number) is the number of new cases arising from a single index case in a fully susceptible population. 
†Total community treatment consists of mass drug administration to all residents in a community where yaws is endemic regardless of clinical or serologic 
evidence of disease. 
‡Total targeted treatment consists of active case finding and treatment of newly identified persons with yaws and their contacts. 
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At the lowest estimates of the force of infection (R0 = 
1.45) and with treatment rounds at 6-month intervals, the 
minimum treatment thresholds required to have a trans-
mission interruption probability of >80% were a coverage 
of >75% of all populations and >8 rounds of treatment (3 
rounds of TCT followed by 5 rounds of TTT). Increasing 
the coverage to 85% reduced the total number of rounds 
required to 5 (1–3 rounds of TCT followed by 2–4 rounds 
of TTT) (Figure 2; Table 2). For comparison, when the 
gap between treatment rounds was extended from 6 to 12 
months, a total of 7 rounds of 85% coverage were required 
(2–3 rounds of TCT and 4–5 rounds of TTT).
At medium estimates of the force of infection 
(R0 = 1.95) and with treatment rounds at 6-month intervals , 
the equivalent thresholds were 90% coverage and a total of 
7 rounds of treatment (2–3 rounds of TCT and 4–5 rounds 
of TTT) (Figure 2; Table 2). When the gap between treat-
ment rounds was increased to 12 months, no combination 
of treatment variables was predicted to have a transmission 
interruption probability of >80%.
At the highest estimates of the force of infection 
(R0 = 3.32) and with treatment rounds at 6-month intervals, 
a total of 8 rounds (3 rounds of TCT and 5 rounds of TTT) 
with 95% coverage were required for a >80% likelihood of 
interrupting transmission (Figure 2; Table 2). When the gap 
between treatment rounds was increased to 12 months, no 
combination of treatment variables was predicted to have a 
probability of interrupting transmission of >80%.
We considered it plausible that, under field conditions, 
the coverage of persons with latent infection would not ex-
ceed 70% in any given round of TTT, because such cases are 
not clinically apparent, and adequate coverage might not be 
achieved by treating the immediate contacts of persons with 
clinical infection. At lower estimates of the force of infection, 
a total of 3 rounds of TCT with 85% coverage and 3 rounds 
of TTT (each with a coverage of persons with active infection 
of 85% and coverage of persons with latent infection of 65%) 
was associated with a >80% probability of interrupting trans-
mission. If only 1 round of TCT was conducted, then cover-
age during TCT needed to be 90% and a total of 5 rounds of 
TTT (each with 90% coverage of persons with active infec-
tion and 65% coverage of persons with latent infection) were 
required. For medium estimates of the force of infection, a 
total of 8 rounds of treatment (3 rounds of TCT and 5 rounds 
of TTT) with a coverage of 90% were required. If only 1 
round of TCT was undertaken, then 95% coverage was re-
quired, followed by 5 rounds of TTT with a 95% coverage of 
persons with active infection and 70% coverage of persons 
with latent infection. Under the highest estimate of the force 
of infection, no combination of treatment variables was as-
sociated with a high probability of interrupting transmission.
Discussion
Our study demonstrates that, with implementation of the 
Morges strategy, interruption of transmission is possible 
in the setting considered. This finding suggests that eradi-
cation of yaws could be achieved, although caution must 
be applied because variability in the parameter estimates 
elsewhere could affect the effectiveness of these strategies. 
The parameter that has the strongest influence on whether 
elimination can be achieved is the transmission rate; that is, 
the rate at which infection occurs given contact between a 
Figure 2. Predicted probability 
of achieving yaws eradication 
given variations in the estimate of 
R0 (basic reproduction number), 
total community treatment 
coverage, number of rounds of 
total community treatment, total 
targeted treatment coverage 
(TTT), and number of rounds of 
TTT. For this graph, we only show 
simulations where the coverage 
of persons with latent cases is the 
same as the coverage of persons 
with active cases during TTT. This 
might overrepresent the actual 
likelihood of achieving eradication 
because the coverage of persons 
with latent cases is probably lower 
than the coverage of persons with 
active cases during TTT. R0, basic 
reproduction number; TCT, total 
community treatment; TTT, total 
targeted treatment.
RESEARCH
26 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 23, No. 1, January 2017
susceptible and an infectious person (online Technical Ap-
pendix Figure). We considered 3 different scenarios of the 
transmission rate of yaws based on serologic data, and our 
estimate of the feasibility of elimination varied consider-
ably depending on these estimates. Further studies to ob-
tain better estimates of the R0 in a range of countries where 
yaws is endemic would be of value to inform improved 
models and programmatic planning. 
A minimum of 8 rounds with coverage of >75% seems 
to be required for a high likelihood of achieving eradication 
but would prove inadequate at our highest estimates of pos-
sible values for R0. The predictions of our model are broad-
ly in keeping with the real-world findings of the successful 
yaws elimination program in India (9), where 7 years of 
consecutive case finding and treatment (analogous to 14 
rounds of TTT with 75% coverage) were conducted. In our 
model, the number of rounds of TTT also had a marked ef-
fect on the likelihood of achieving eradication, especially 
when coverage of persons with latent cases was limited to 
<70%. In these settings, the required number of rounds of 
treatment to interrupt transmission increased considerably.
Relatively few data are available on the transmission 
rate of yaws. Even within yaws-endemic countries, the 
prevalence of yaws varies markedly. Studies in the Pacific 
have found a seroprevalence of antitreponemal antibodies 
of >30% in several communities (7,17) and a prevalence of 
clinical yaws of ranging from 2.5% to 5% in communities 
before mass treatment. The prevalence of yaws is mark-
edly lower in many yaws-endemic countries in West Africa 
(20), but limited community-based seroprevalence data are 
available to inform our understanding of disease transmis-
sion there. 
We modeled a range of estimates of R0 from 1.08 to 
3.32 based on seroprevalence data and expert opinion. 
Given the substantial influence of these estimates on the 
likely outcome of community mass treatment, further stud-
ies to better understand disease transmission and how this 
varies within and between endemic communities would be 
of value. Ideally, these studies would obtain community-
level, age-specific seroprevalence data that could be used 
to calculate the force of infection. No perfect serologic 
marker can be used for this task. Traditional treponemal se-
rology combines a treponemal test, which reflects lifetime 
exposure but remains positive for life, with a nontrepone-
mal test, the titer of which rises and falls after treatment. It 
is therefore not possible to use seroprevalence data to dis-
tinguish persons who have been infected many times from 
those who have been infected once, and seroprevalence 
estimates are likely to underestimate the actual force of in-
fection. For this study, we calculated the force of infection 
while relying on treponemal serology alone, which should 
provide a more accurate estimate of the force of infection 
than if we used dual-positive serology. It remains, how-
ever, an imperfect measure.
Our model predicts that high coverage is required in 
all rounds of treatment to make yaws eradication feasible. 
Data from the previous WHO and United Nations Chil-
dren’s Fund mass treatment campaign have highlighted the 
importance of achieving high coverage of persons with la-
tent cases of yaws (21) and that treatment of persons with 
active cases alone is insufficient to interrupt transmission. 
These factors were important considerations in the adoption 
as part of the Morges strategy of an initial round of TCT re-
gardless of the prevalence of active disease in a community. 
Given the high coverage requirement, particularly of per-
sons with latent cases, and the relatively high fixed-costs of 
reaching yaws-endemic communities (14) compared with 
the relatively low costs of generic azithromycin, it might 
be preferable to conduct multiple rounds of TCT before the 
switch to TTT. Such a recommendation would be in line 
with the original Morges strategy (22), which recommend-
ed that additional rounds of TCT could be considered if 
the coverage achieved in the initial round of treatment was 
<90% or if access to yaws-endemic communities was diffi-
cult. A switch to multiple rounds of community mass treat-
ment might also facilitate integration with other neglected 
tropical diseases mass drug administration programs in 
countries that are also frequently based on whole commu-
nity mass treatment (23), although our model predicted a 
higher probability of achieving eradication with biannual 
 
 
 
Table 2. Indicative predicted coverage and number of rounds of treatment required to achieve yaws eradication 
Predicted probability by estimated R0 
Treatment every 6 mo 
 
Treatment every 12 mo 
Coverage required Total no. rounds* Coverage required Total no. rounds* 
80% predicted probability of eradication      
 Low R0 (1.45, 95% CI 1.01–2.14) 75% 8  85% 7 
 Medium R0 (1.95, 95% CI 1.38–2.91) 90% 7  † † 
 High R0 (2.47, 95% CI 1.7–3.68) 95% 8  † † 
100% predicted probability of eradication      
 Low R0 (1.45, 95% CI 1.01–2.14) 85% 8  95% 6 
 Medium R0 (1.95, 95% CI 1.38–2.91) † †  † † 
 High R0 (2.47, 95% CI 1.7–3.68) † †  † † 
*R0 (basic reproduction number) is the number of new cases arising from a single index case in a fully susceptible population. For this table, the number 
of rounds of total community treatment and total targeted treatment is combined (e.g., a total of 7 rounds could be 3 rounds of total community treatment 
and 4 rounds of total targeted treatment or, alternatively, 2 rounds of total community treatment and 5 rounds of total targeted treatment). Data are 
indicative only, and in some settings, higher coverage would allow a reduction in the total number of rounds required (see text and Figure 2).  
†No combination of treatment variables was associated with the stated eradication probability. 
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treatment. Further studies to help determine the optimum 
strategy for achieving high coverage of persons with latent 
cases during the TTT phase of eradication efforts should 
be considered (e.g., studies of the spatial epidemiology of 
latent yaws cases in relation to persons with active cases 
in both pre– and post–mass drug administration settings or 
studies of whether additional mass treatment rounds spe-
cifically targeting children might be beneficial).
Our study has several limitations. Most notably, we 
lack accurate estimates for several disease parameters. The 
parameters used are derived from expert opinion and data 
from the Pacific region, and the transmission dynamics of 
yaws might be different in other regions of the world. How-
ever, the disease parameters used in this study are broadly 
in line with those used by other models of yaws transmis-
sion (14). We tested a range of coverage estimates for com-
munity mass treatment, but we did not factor in the pos-
sibility that some persons might be systematically missed 
during mass treatment campaigns, a phenomenon that has 
been observed in control efforts for other neglected tropical 
diseases (24). The current Morges strategy does not include 
adjunctive elements, such as water, sanitation, and hygiene 
interventions, in addition to mass treatment, although some 
studies suggest that improved access to water and sanitation 
is associated with a decreased risk for yaws (17). We did not 
include a secular trend in our model, and such a trend could 
be anticipated to further increase the likelihood of yaws 
eradication being achieved. Our model was designed to as-
sess the feasibility of achieving yaws eradication in the near 
future, driven by the current WHO strategy, and in those 
conditions any effect of a secular trend could be expected to 
be minimal compared with the substantial impact of com-
munity mass treatment. Previous models have shown that 
secular trends are unlikely to substantially affect the cost-
effectiveness of mass treatment (14); however, those mod-
els were based on an assumption of 90%–99% coverage in 
a single TCT round and 100% coverage of index patients 
and their contacts in the TTT round. More generally, we 
used a single-model structure that is simplified by modeling 
persons as being in 1 of a small number of disease-related 
compartments at any time and considering contact to occur 
at random. Uncertainty in model structure relating to dis-
ease progression and the probability of contact means that 
our findings should be interpreted carefully and potentially 
reassessed as elimination strategies are being applied.
In conclusion, our study assessed the theoretical 
achievability of worldwide yaws eradication and repre-
sents an important milestone in reaching the WHO’s eradi-
cation target. We have defined programmatic thresholds 
that might need to be met to achieve yaws eradication and 
identified key research questions to be addressed to inform 
refinements of the model and the worldwide roll-out of 
treatment strategies.
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